The Ministry of Commerce released the "Statistical Analysis Report on the Operation of the Pharmaceutical Distribution Industry in 2011", which has statistically analyzed the overall scale of the pharmaceutical distribution industry, purchases, sales, inventory, and operations of pharmaceutical wholesale and retail companies, and the distribution of basic medicines for the country, and Development trends are forecasted.
The "Report" pointed out that in 2011, the pharmaceutical distribution industry under the guidance of the "Outline of the National Pharmaceutical Distribution Industry Development Plan (2011-2015)" actively promoted the adjustment of economic structure and the transformation and upgrading of the development mode, the speed of mergers and reorganizations of enterprises, and the degree of market concentration. The circulation efficiency and management modernization level have been further enhanced. Drug wholesalers have taken the initiative in transitioning from traditional medicine wholesalers to medical and health industry service providers; pharmaceutical retailers have made strategic adjustments, actively responded to difficulties and challenges, accelerated the development of chain operations, and effectively promoted Increased market competitiveness. The industry as a whole is in a period of transitional development and has made unremitting efforts to maintain growth, adjust structure, promote reform, and benefit people's livelihood, and has further increased its contribution to economic growth.
The establishment of a statistical system for the pharmaceutical distribution industry is an important basic work undertaken by the Ministry of Commerce after it assumes the management responsibilities of the pharmaceutical circulation industry. This is the second time that the Ministry of Commerce has released the annual statistical analysis report of the industry. In the future, the Ministry of Commerce will continue to count and publish the basic information of the pharmaceutical distribution industry and promote the healthy development of the pharmaceutical distribution industry.
Regional market competition grew more intense <br> <br> data show that since last year, the scale of domestic pharmaceutical distribution to maintain a rapid growth, but the level of efficiency of the sector is not optimistic. In the first quarter of 2012, medical and pharmaceutical business revenues increased by 29.25% year-on-year, second only to the medical services sector, but the total net profit for the period decreased by 14.07% year-on-year, which was only better than the chemical and pharmaceutical sector. According to industry sources, the overall profitability of the pharmaceutical biotechnology industry has affected the profitability of the pharmaceutical distribution industry. Data show that the first quarter of the biomedical industry operating income growth of 20.30%, but the net profit only slightly increased by 1.38% year-on-year, the industry's downturn has hit the intermediate circulation of profitability.
In spite of this, the competitive situation in which the pharmaceutical distribution industry tends to become more heated has not been weakened, and the market segregation of the industry giants has become more intense. According to the latest data from the Ministry of Commerce, the main business income of the top 100 pharmaceutical wholesalers in 2011 accounted for 73% of the total market size in the same period, an increase of 3% year-on-year. The top 10 companies' main business income accounted for 62.5% of the top 100. Among them, the three major giants of Sinopharm Group, Shanghai Pharmaceutical Group and China Resources Medicine accounted for 100% of their main business revenues, which increased by 7.6% year-on-year.
The “Statistical Analysis Report on Pharmaceutical Circulation Industry Operation in 2011†of the Ministry of Commerce believes that the adjustment of the industry structure has accelerated, and that mergers and restructurings across regions have been in the ascendant. Large enterprises have expanded rapidly in second-tier and third-tier cities and grass-roots medical markets and gradually formed the Sinopharm Group, Shanghai Pharmaceutical Group, and China Resources Pharmaceutical and National Drug Distribution Group represented by Kyushu Tong (600998).
The business development of privately-owned circulation enterprises is strong and the operating efficiency is optimistic. According to the data from the Ministry of Commerce, the main income of state-owned and state-controlled enterprises in the distribution enterprises above designated size accounted for 59.5% of the company’s total direct income, while the profit accounted for 54.2%; the main income of joint-stock enterprises accounted for 22.8 of the industry’s total revenue. %, but profits accounted for 26.8%. Of the pharmaceutical commercial enterprises that have disclosed their performance forecast, Ruikang Pharmaceutical (002589), Jiashitang (002462), and Zhejiang Zhenyuan (000705) expect that the 2012 interim results will increase by more than 50%. Kyushu Express (600998), which has a strong main business, has achieved a cumulative increase of 33.16% since the second quarter, ranking first in the same sector.
Circulation information technology investment surge <br> <br> pharmaceutical distribution industry, market structure changes while promoting investment in information technology to enhance the industry. In 2011, investment in information system construction increased 34.8% over the previous year. The Ministry of Commerce stated that the acquisition and reorganization of inter-provincial group companies is active, and the input of information systems integration has increased, which is the main reason for the rapid growth of information construction investment.
According to reports, in the construction of modern pharmaceutical logistics, the nationwide logistics and distribution network has entered an intensive construction period. Large and medium-sized drug distribution enterprises have placed important nodes on strategically located prefecture-level cities while speeding up the distribution of provincial logistics centers. Some drug distribution companies began to provide supply chain integration solutions, promote the pre-docking of distributors' content management systems and hospital information systems, realized automatic replenishment of central drug stores and relatively zero inventory management, and improved the efficiency of drug circulation in hospitals. Drug losses and logistics costs.
This is because the difference in the selling price is no longer a reliable source of profit. The "Report" stated that this model will be challenged by the state's essential medicine system, bidding policies, and price cuts for pharmaceuticals, and the industry gross margin will be further reduced. In fact, this challenge has gradually been confirmed. The data shows that half of the A-share pharmaceutical business enterprises' gross profit margin fell in comparison to the previous period since 2011. The gross profit margins of Sinopharm (600511), Nanjing Pharmaceutical (600713), and Shanghai Pharmaceutical (601607) all declined to some extent.
The pharmaceutical industry's business model has accelerated its innovation. Among them, the Internet pharmaceutical e-commerce is developing rapidly. In 2010, there were 18 companies approved to launch Internet drug trading services and 54 in 2011. The scope of services includes providing personal consumers with drugs, trading drugs with other companies, and third-party transaction service platforms. According to the “Report†of the Ministry of Commerce, it is expected that in the coming period, e-commerce in pharmaceuticals will be a hot topic in the circulation industry.
The problem of outstanding loans to drug wholesalers in hospitals was prominent. In 2011, the company’s asset-liability ratio was as high as 74.1%. According to data from a typical survey conducted by the China Pharmaceutical Business Association on 2011 accounts receivables of 44 drug wholesale enterprises in 25 provinces and cities, the average number of receivables turnover days for pharmaceutical wholesale enterprises for public medical institutions is 131 days. The total amount of 43.47 billion yuan, accounting for 36.3% of the operating income of public medical institutions. Medical institutions have severely overwhelmed the funds of wholesale companies, which not only led to the heavy burden of financial costs on wholesale companies that rely on bank loans to purchase drugs, but also seriously affected the cash flow status of the entire pharmaceutical circulation industry and restricted the further improvement of circulation efficiency.
In 2011, the demand for the pharmaceutical circulation market was active and the purchase and sales of the industry grew steadily. The total sales value of the drug distribution industry reached 942.6 billion yuan, which was a year-on-year increase of 23% after deducting incomparable factors. Among them, the pharmaceutical retail market sales reached 188.5 billion yuan, the growth rate stabilized at about 20%. By the end of 2010, there were a total of 13,500 drug wholesalers nationwide; the total number of retail pharmacy stores was 399,000, including 2,310 drug retail chain stores, 137,000 stores under management, and 262,000 retail drugstores.
The "Report" shows that the market concentration of pharmaceutical circulation is further increasing. In 2011, the main business income of the top 100 drug wholesalers accounted for 73% of the total market size of the national market over the same period, an increase of 3 percentage points over the previous year. The top three group companies accounted for 42.0% of the top 100 main business revenues, of which: China Pharmaceutical Group's main business income has taken the lead in breaking through the 100 billion yuan mark, and Shanghai Pharmaceutical Group and China Resources Medicine Holdings both exceeded RMB 40 billion. Looking at the sales of the top 100 companies in the retail chain, there are 5 sales of more than 3 billion yuan, 9 of them are more than 2 billion yuan, and 20 are of more than 1 billion yuan. The concentration of pharmaceutical retail industry was further increased: The sales of the top 5 companies accounted for 26% of the top 100 sales, up 2% year-on-year; the sales of the top 10 companies accounted for 44% of the top 100, up 3% year-on-year; the top 20 Sales accounted for 61% of the top 100, an increase of 3 percentage points year-on-year.
The pace of foreign investment in the pharmaceutical circulation has accelerated. At present, the leading domestic companies have nearly saturated their domestic market share, and they are optimistic about China's huge market, hoping to find new opportunities for growth. In recent years, investment by foreign pharmaceutical giants in China is no longer confined to the pharmaceutical industry, but has been gradually infiltrated into other sectors of the industry chain, from drug manufacturing to pharmaceutical distribution and retail terminals, such as the well-known US healthcare service provider Conde Le. The Group acquired Yongyu Pharmaceutical (China) Co., Ltd. The British Booth Group also expanded its investment in China.
The "Report" pointed out that in 2011, the pharmaceutical distribution industry under the guidance of the "Outline of the National Pharmaceutical Distribution Industry Development Plan (2011-2015)" actively promoted the adjustment of economic structure and the transformation and upgrading of the development mode, the speed of mergers and reorganizations of enterprises, and the degree of market concentration. The circulation efficiency and management modernization level have been further enhanced. Drug wholesalers have taken the initiative in transitioning from traditional medicine wholesalers to medical and health industry service providers; pharmaceutical retailers have made strategic adjustments, actively responded to difficulties and challenges, accelerated the development of chain operations, and effectively promoted Increased market competitiveness. The industry as a whole is in a period of transitional development and has made unremitting efforts to maintain growth, adjust structure, promote reform, and benefit people's livelihood, and has further increased its contribution to economic growth.
The establishment of a statistical system for the pharmaceutical distribution industry is an important basic work undertaken by the Ministry of Commerce after it assumes the management responsibilities of the pharmaceutical circulation industry. This is the second time that the Ministry of Commerce has released the annual statistical analysis report of the industry. In the future, the Ministry of Commerce will continue to count and publish the basic information of the pharmaceutical distribution industry and promote the healthy development of the pharmaceutical distribution industry.
Regional market competition grew more intense <br> <br> data show that since last year, the scale of domestic pharmaceutical distribution to maintain a rapid growth, but the level of efficiency of the sector is not optimistic. In the first quarter of 2012, medical and pharmaceutical business revenues increased by 29.25% year-on-year, second only to the medical services sector, but the total net profit for the period decreased by 14.07% year-on-year, which was only better than the chemical and pharmaceutical sector. According to industry sources, the overall profitability of the pharmaceutical biotechnology industry has affected the profitability of the pharmaceutical distribution industry. Data show that the first quarter of the biomedical industry operating income growth of 20.30%, but the net profit only slightly increased by 1.38% year-on-year, the industry's downturn has hit the intermediate circulation of profitability.
In spite of this, the competitive situation in which the pharmaceutical distribution industry tends to become more heated has not been weakened, and the market segregation of the industry giants has become more intense. According to the latest data from the Ministry of Commerce, the main business income of the top 100 pharmaceutical wholesalers in 2011 accounted for 73% of the total market size in the same period, an increase of 3% year-on-year. The top 10 companies' main business income accounted for 62.5% of the top 100. Among them, the three major giants of Sinopharm Group, Shanghai Pharmaceutical Group and China Resources Medicine accounted for 100% of their main business revenues, which increased by 7.6% year-on-year.
The “Statistical Analysis Report on Pharmaceutical Circulation Industry Operation in 2011†of the Ministry of Commerce believes that the adjustment of the industry structure has accelerated, and that mergers and restructurings across regions have been in the ascendant. Large enterprises have expanded rapidly in second-tier and third-tier cities and grass-roots medical markets and gradually formed the Sinopharm Group, Shanghai Pharmaceutical Group, and China Resources Pharmaceutical and National Drug Distribution Group represented by Kyushu Tong (600998).
The business development of privately-owned circulation enterprises is strong and the operating efficiency is optimistic. According to the data from the Ministry of Commerce, the main income of state-owned and state-controlled enterprises in the distribution enterprises above designated size accounted for 59.5% of the company’s total direct income, while the profit accounted for 54.2%; the main income of joint-stock enterprises accounted for 22.8 of the industry’s total revenue. %, but profits accounted for 26.8%. Of the pharmaceutical commercial enterprises that have disclosed their performance forecast, Ruikang Pharmaceutical (002589), Jiashitang (002462), and Zhejiang Zhenyuan (000705) expect that the 2012 interim results will increase by more than 50%. Kyushu Express (600998), which has a strong main business, has achieved a cumulative increase of 33.16% since the second quarter, ranking first in the same sector.
Circulation information technology investment surge <br> <br> pharmaceutical distribution industry, market structure changes while promoting investment in information technology to enhance the industry. In 2011, investment in information system construction increased 34.8% over the previous year. The Ministry of Commerce stated that the acquisition and reorganization of inter-provincial group companies is active, and the input of information systems integration has increased, which is the main reason for the rapid growth of information construction investment.
According to reports, in the construction of modern pharmaceutical logistics, the nationwide logistics and distribution network has entered an intensive construction period. Large and medium-sized drug distribution enterprises have placed important nodes on strategically located prefecture-level cities while speeding up the distribution of provincial logistics centers. Some drug distribution companies began to provide supply chain integration solutions, promote the pre-docking of distributors' content management systems and hospital information systems, realized automatic replenishment of central drug stores and relatively zero inventory management, and improved the efficiency of drug circulation in hospitals. Drug losses and logistics costs.
This is because the difference in the selling price is no longer a reliable source of profit. The "Report" stated that this model will be challenged by the state's essential medicine system, bidding policies, and price cuts for pharmaceuticals, and the industry gross margin will be further reduced. In fact, this challenge has gradually been confirmed. The data shows that half of the A-share pharmaceutical business enterprises' gross profit margin fell in comparison to the previous period since 2011. The gross profit margins of Sinopharm (600511), Nanjing Pharmaceutical (600713), and Shanghai Pharmaceutical (601607) all declined to some extent.
The pharmaceutical industry's business model has accelerated its innovation. Among them, the Internet pharmaceutical e-commerce is developing rapidly. In 2010, there were 18 companies approved to launch Internet drug trading services and 54 in 2011. The scope of services includes providing personal consumers with drugs, trading drugs with other companies, and third-party transaction service platforms. According to the “Report†of the Ministry of Commerce, it is expected that in the coming period, e-commerce in pharmaceuticals will be a hot topic in the circulation industry.
The problem of outstanding loans to drug wholesalers in hospitals was prominent. In 2011, the company’s asset-liability ratio was as high as 74.1%. According to data from a typical survey conducted by the China Pharmaceutical Business Association on 2011 accounts receivables of 44 drug wholesale enterprises in 25 provinces and cities, the average number of receivables turnover days for pharmaceutical wholesale enterprises for public medical institutions is 131 days. The total amount of 43.47 billion yuan, accounting for 36.3% of the operating income of public medical institutions. Medical institutions have severely overwhelmed the funds of wholesale companies, which not only led to the heavy burden of financial costs on wholesale companies that rely on bank loans to purchase drugs, but also seriously affected the cash flow status of the entire pharmaceutical circulation industry and restricted the further improvement of circulation efficiency.
In 2011, the demand for the pharmaceutical circulation market was active and the purchase and sales of the industry grew steadily. The total sales value of the drug distribution industry reached 942.6 billion yuan, which was a year-on-year increase of 23% after deducting incomparable factors. Among them, the pharmaceutical retail market sales reached 188.5 billion yuan, the growth rate stabilized at about 20%. By the end of 2010, there were a total of 13,500 drug wholesalers nationwide; the total number of retail pharmacy stores was 399,000, including 2,310 drug retail chain stores, 137,000 stores under management, and 262,000 retail drugstores.
The "Report" shows that the market concentration of pharmaceutical circulation is further increasing. In 2011, the main business income of the top 100 drug wholesalers accounted for 73% of the total market size of the national market over the same period, an increase of 3 percentage points over the previous year. The top three group companies accounted for 42.0% of the top 100 main business revenues, of which: China Pharmaceutical Group's main business income has taken the lead in breaking through the 100 billion yuan mark, and Shanghai Pharmaceutical Group and China Resources Medicine Holdings both exceeded RMB 40 billion. Looking at the sales of the top 100 companies in the retail chain, there are 5 sales of more than 3 billion yuan, 9 of them are more than 2 billion yuan, and 20 are of more than 1 billion yuan. The concentration of pharmaceutical retail industry was further increased: The sales of the top 5 companies accounted for 26% of the top 100 sales, up 2% year-on-year; the sales of the top 10 companies accounted for 44% of the top 100, up 3% year-on-year; the top 20 Sales accounted for 61% of the top 100, an increase of 3 percentage points year-on-year.
The pace of foreign investment in the pharmaceutical circulation has accelerated. At present, the leading domestic companies have nearly saturated their domestic market share, and they are optimistic about China's huge market, hoping to find new opportunities for growth. In recent years, investment by foreign pharmaceutical giants in China is no longer confined to the pharmaceutical industry, but has been gradually infiltrated into other sectors of the industry chain, from drug manufacturing to pharmaceutical distribution and retail terminals, such as the well-known US healthcare service provider Conde Le. The Group acquired Yongyu Pharmaceutical (China) Co., Ltd. The British Booth Group also expanded its investment in China.
BPAP20 AUTO / BPAP25 AUTO is a professional solution for OSA patient who have trouble tolerating CPAP device.
4.3-inch TFT Color LCD Screen, Displaying A Number Of Monitored Parameters; Respiration Pressure, Flow Rate Waveform Display, Clear And Accurate; Smart Start And Stop Breathing; Multiple Alarm Functions; Intelligent Automatic Leak Compensation. The New Integrated Heated Humidifier, According To The Different Needs Of Patients, Set Up Multiple Profiles Of Temperature And Humidity, Multiple Anti-Reflux Design, Safe To Use. Built-In High-Capacity Smart Card Can Be Used For Data Recording, The Recording Time, Respiratory Status, Can Assess The Therapeutic Effect, And Print Reports.
BPAP 20 Auto,BPAP 25 Auto,Non Invasive Ventilation Hood,Non Invasive Ventilation Oxygen
Shenyang RMS MEDICAL TECH CO.,LTD , https://www.medicalrms.com